Switzerland At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges with the findings published in the Swiss Biotech Report 2023. The organisation also celebrated recent industry successes with its Swiss…
USA Founded in 1980 “at the dawn of a biotechnology revolution,” Amgen has held its ground throughout its more than 40-year history with innovative approaches to drug discovery that have led to a number of breakthrough therapies. Chairman and CEO Bob Bradway recently spoke to the Money Maze podcast about the…
Hong Kong Commonly regarded ‘the father of Hong Kong biotechnology’, Professor Lo Yuk Lam has had a hand in almost all of the city’s biotech success stories, including those of Michael Yang and Dennis Lo. Professor Lo has been heavily involved in several Hong Kong governmental committees, is an Honorary Professor of…
Taiwan In an important milestone for Taiwan’s biotech industry, Diamond Biofund – one of the territory’s most well-established venture capital (VC) funds – became the first such firm to list on the Taiwan Stock Exchange last month. Diamond, defines itself as an “evergreen” biotech venture capital fund, meaning that, unlike…
Hong Kong Well established as Asia’s leading financial services and trading hub, Hong Kong is now looking to better position itself as a centre for biotechnology investment and start-ups. However, in a risk-averse investment environment with strong basic research but little tradition of translational science, such a transformation will take time, capital,…
Korea A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation hub in Boston, US; a list of some of the country’s most important biotech companies; and Medtronic’s move to purchase…
Hong Kong As managing director of the CR-CP Life Science Fund, whose shareholders, CR Group and CP Group, are on the Fortune Global 500 List, Da Liu leads investments in life sciences companies globally, especially those in emerging sectors such as RNA therapeutics and cancer screening. In conversation with PharmaBoardroom, Liu discusses…
Hong Kong A groundbreaking research scientist noted for his work in non-invasive blood-based diagnoses, Professor Dennis Lo currently holds a number of positions at the Chinese University of Hong Kong (CUHK). Lo, whose work was first commercialised via the company Cirina – later acquired by GRAIL – outlines his current research focus on…
Belgium Belgium’s Flanders region is a hotbed of biotech excellence, with numerous examples of university spin-offs being translated into commercial-stage companies and many of those later acquired by Big Pharma. Wouter Piepers of cluster organisation flanders.bio outlines the fundamentals behind this success story, and what potential future investors in Belgian biotech…
Hong Kong Professor Michael Yang of City University of Hong Kong (CityU) introduces the ‘HK Tech 300‘ programme he oversees, the largest university-based entrepreneurship programme in Asia. Drawing on his own experience as co-founder of Prenetics and Cellomics, biotech companies based on technologies developed in his laboratory at CityU, Professor Yang assesses…
Switzerland Taken from the recently published Swiss Biotech Report 2023, these figures cover major public and private financing transactions in Swiss biotech in the past year; major financing categories; capital investments in Swiss biotech companies; revenues, R&D expenses, profit/loss and liquidity; as well as well as the total number of biotech…
USA While the COVID-19 pandemic was a global wake-up call for many, life sciences stakeholders argue that not enough is being done to address the rising threats of further health crises and equate health security with national security, a necessity that requires consistent public funding. In addition, as a recent panel…
See our Cookie Privacy Policy Here